Eye, Ear & VisionDuring active treatment, RLRL was associated with less axial elongation than OK over 3 years in this cohort. Both treatments showed acceptable safety profiles.
Study · September 10, 2026 · Nie A et al.
Eye, Ear & VisionRLRL exerted refractive state-dependent effects on ocular growth in guinea pigs, attenuating myopic progression under myopic conditions and promoting refractive emmetropization under hyperopic conditions.
Study · August 12, 2026 · Liu T et al.
Devices & DosimetryNo adverse events were reported. MLS-based PBM was safe and associated with improvement in clinical signs of canine OE.
Study · August 3, 2026 · Gesuete F et al.
Eye, Ear & VisionRLRL slows ocular elongation and myopia progression. Recent studies provide reassuring evidence regarding its long-term safety when recommended treatment protocols are followed.
Review · July 10, 2026 · Domínguez-Morras C et al.
Eye, Ear & VisionCombining RLRL therapy with ortho-k is an effective and safe myopia control strategy in Caucasian Spanish children, supporting the potential generalisability of the synergistic effect across diverse ethnic groups.
Trial · June 22, 2026 · Fernández Fidalgo MJ et al.
Eye, Ear & VisionPBM significantly reduced drusen burden and improved visual function in early and intermediate dAMD over 12 months, with an excellent safety profile.
Study · June 8, 2026 · Iovino C et al.
Eye, Ear & VisionThe study indicates a seminal role of Beclin1 in maintaining retinal integrity and it defines the vulnerability of various retinal layers in the spreading of Beclin1-dependent retinal degeneration.
Study · May 4, 2026 · Biagioni F et al.
OtherAdjunctive LLLT was associated with a sustained increase in lipid layer thickness compared with IPL alone.
Trial · April 15, 2026 · Kharuhayothin C et al.
Eye, Ear & VisionRLRL was associated with duration-dependent reductions in myopia progression up to 1 year. Reported structural parameters remained stable and adverse events were generally mild.
Review · March 18, 2026 · Lin LY et al.
Eye, Ear & VisionStudy · March 1, 2026 · Prenner S et al.
Eye, Ear & VisionFindings from this single-arm pilot study suggest that LLLT is associated with improved tear film stability and reduced MMP9 levels in patients with mild to moderate DED.
Study · February 9, 2026 · Antwi A et al.
Eye, Ear & VisionWe developed and validated an interpretable machine learning model that accurately predicts short- and long-term outcomes of RLRL therapy in children.
Study · January 7, 2026 · Hu X et al.
Skin & Wound HealingThese preliminary findings support the safety and efficacy of this combination approach. Further studies are needed to optimize this approach.
Trial · December 17, 2025 · Wu X et al.
Eye, Ear & VisionBACKGROUND: Photobiomodulation therapy (PBMT)-a noninvasive therapeutic strategy-employs low-level red or near-infrared light to regulate cellular bioenergetics, reduce oxidative stress, and modulate inflammation.
Study · November 20, 2025 · Choy S et al.
Eye, Ear & VisionMGX, IPL+MGX, and LipiFlow were all effective in improving signs and symptoms in severe MGD. IPL+MGX provide the most consistent long-term benefits in stabilizing tear film and alleviating symptoms..
Trial · October 27, 2025 · Han Y et al.
Eye, Ear & VisionWith improved imaging techniques and targeted treatments, clinicians can more precisely evaluate disease severity and offer more effective interventions.
Review · September 30, 2025 · Kappos N et al.
Eye, Ear & VisionSubgroup analysis found comparable efficacy between the extreme and high myopia groups. These results indicate RLRL is a safe, non-invasive option for managing extreme myopia in children, with meaningful clinical value.
Study · August 26, 2025 · Tian L et al.
Devices & DosimetryIn addition, for 447-nm exposure conditions leading to damage considered neither purely photothermal nor photochemical, there is a reduced requirement for the thermal component for cell death.
Study · August 8, 2025 · Pope NJ et al.